Beamon Agarwal, MD, PhD
Adviser and Chief Medical Officer
Dr. Agarwal is a highly qualified pathologist who brings in many years of translational research and pathology experience in the fields of head and neck squamous cell carcinoma (HNSCC), breast cancer, lymphomas and trained at Tata Memorial Center, India and University of Pennsylvania. Dr. Agarwal has extensive experience in both neoplastic and non-neoplastic pathology in the eastern and western world and with animal histopathology.
Steven M. Opal, MD
Brown University, Rhode Island
Dr. Opal has worked on preclinical and clinical trials of sepsis for more than 30 years and has extensive experience with localized infection models in mice and rats with immunotherapeutic and Toll Like Receptor (TLR) inhibitors. He serves as an adviser to design these preclinical experiments and will work with us in clinical trials. He served as the principal investigator for the Phase-III clinical trial of Asahi’s ART-123 which is approved for marketing for sepsis.
Stella M. Robertson, PhD
25+ years Pharmaceutical industry R&D with global project management, product development, and clinical expertise.
5+ years mentor, board member and scientific adviser with early stage companies, and VC/angel investing.